Search research articles
Contact Us
Filters
Showing results (361-370 of 464) with videos related to
Page
of 47
Sort By:
Gastroenterology
|
July 24, 2019
Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease
Pieter Hindryckx, Vipul Jairath, Guangyong Zou, et al.
The New England Journal of Medicine
|
May 4, 2017
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J Sandborn, Chinyu Su, Bruce E Sands, et al.
Lancet (London, England)
|
September 7, 2015
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna, Brian Bressler, Barrett G Levesque, et al.
Inflammatory Bowel Diseases
|
September 19, 2025
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease
Stefan Schreiber, Scott D Lee, C Janneke van der Woude, et al.
Inflammatory Bowel Diseases
|
October 24, 2019
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease
James D Lewis, Paul Rutgeerts, Brian G Feagan, et al.
Journal of Crohn'S & Colitis
|
September 30, 2016
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Edward V Loftus, Jean-Frédéric Colombel, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
January 11, 2017
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease
Reena Khanna, GuangYong Zou, Larry Stitt, et al.
The American Journal of Gastroenterology
|
April 19, 2017
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease
Reena Khanna, GuangYong Zou, Larry Stitt, et al.
The New England Journal of Medicine
|
October 19, 2012
Ustekinumab induction and maintenance therapy in refractory Crohn's disease
William J Sandborn, Christopher Gasink, Long-Long Gao, et al.
Lancet (London, England)
|
December 20, 2024
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
David T Rubin, Jessica R Allegretti, Julián Panés, et al.
Page
of 47
Search research articles
Search
Showing results (361-370 of 464) with videos related to
Sort By:
Page
of 47
Gastroenterology
|
July 24, 2019
Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease
Pieter Hindryckx, Vipul Jairath, Guangyong Zou, et al.
The New England Journal of Medicine
|
May 4, 2017
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J Sandborn, Chinyu Su, Bruce E Sands, et al.
Lancet (London, England)
|
September 7, 2015
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna, Brian Bressler, Barrett G Levesque, et al.
Inflammatory Bowel Diseases
|
September 19, 2025
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease
Stefan Schreiber, Scott D Lee, C Janneke van der Woude, et al.
Inflammatory Bowel Diseases
|
October 24, 2019
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease
James D Lewis, Paul Rutgeerts, Brian G Feagan, et al.
Journal of Crohn'S & Colitis
|
September 30, 2016
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Edward V Loftus, Jean-Frédéric Colombel, Brian G Feagan, et al.
The American Journal of Gastroenterology
|
January 11, 2017
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease
Reena Khanna, GuangYong Zou, Larry Stitt, et al.
The American Journal of Gastroenterology
|
April 19, 2017
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease
Reena Khanna, GuangYong Zou, Larry Stitt, et al.
The New England Journal of Medicine
|
October 19, 2012
Ustekinumab induction and maintenance therapy in refractory Crohn's disease
William J Sandborn, Christopher Gasink, Long-Long Gao, et al.
Lancet (London, England)
|
December 20, 2024
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
David T Rubin, Jessica R Allegretti, Julián Panés, et al.
Page
of 47